Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV20 in Lymphoma Survivors After Anti-CD20 Therapy
NCT06049134Phase 4Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Prevnar 20 in pneumococcal infection, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2023; status: active, not recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06049134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049134.